Parkinson's disease: evolution of cognitive impairment and CSF Aβ 1-42 profiles in a prospective longitudinal study

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170. doi: 10.1136/jnnp-2018-318956. Epub 2018 Sep 25.

Abstract

Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD).

Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men).

Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1-42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up.

Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ1-42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.

Keywords: CSF; Parkinson; amyloid-beta; longitudinal.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers / cerebrospinal fluid
  • Case-Control Studies
  • Cognitive Dysfunction / cerebrospinal fluid*
  • Cognitive Dysfunction / etiology
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Parkinson Disease / cerebrospinal fluid*
  • Parkinson Disease / psychology*
  • Peptide Fragments / cerebrospinal fluid*
  • Prospective Studies
  • tau Proteins / cerebrospinal fluid

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins